Albany Molecular Research (AMRI) said today it has agreed to be acquired by affiliates of The Carlyle Group and GTCR for about $922 million cash in a deal that continues consolidation among contract development and manufacturing organizations (CDMOs).

Founded in 1991, AMRI is a global contract research and manufacturing organization offering services across the drug development pathway, from target discovery and lead optimization through formulation development and sterile fill/finish.

In recent years, AMRI has expanded through acquisitions. Last year, AMRI bought Prime European Therapeuticals (Euticals), an active pharmaceuticals ingredients (API) manufacturer, for approximately $358 million. And in 2015, AMRI acquired Gadea Pharmaceutical Group for $174 million, in a deal intended to expand the buyer’s portfolio of APIs, as well as its presence outside the U.S. 

“This transaction is a strong endorsement of our strategy,” AMRI president and CEO William S. Marth said in a statement. “Given their deep healthcare industry expertise and financial resources, Carlyle and GTCR are highly attractive partners for us and offer a compelling opportunity to accelerate our growth and enhance delivery of world-class solutions to our customers.”

The biggest consolidation deal among CDMOs was announced last month, when Thermo Fisher Scientific said it planned to acquire Patheon for approximately $7.2 billion from affiliates of JLL Partners and Royal DSM.  However, an even bigger deal may be brewing, as speculation emerged earlier this year that LabCorp was in talks to acquire







This site uses Akismet to reduce spam. Learn how your comment data is processed.